In this article, we will list the 5 Oversold Small Cap Stocks to Buy Now. Please visit 10 Oversold Small Cap Stocks to Buy Now if you’d like to see an extended list and the methodology behind it.

5. TAT Technologies Ltd. (NASDAQ:TATT)

TAT Technologies Ltd. (NASDAQ:TATT) is one of the 10 oversold small cap stocks to buy now.

On April 8th, B. Riley initiated its coverage of TAT Technologies Ltd. (NASDAQ:TATT), assigning a Buy rating with a $61 price target for the stock. This results in an impressive upside of almost 70% at the current level. The firm highlighted that TAT is one of the key players in the market, offering maintenance, repair, and overhaul services and original equipment manufacturing solutions to the commercial and military aerospace, as well as ground defense industries.

B. Riley mentioned that TAT presents a great investment prospect as an under-covered and aviation-focused company. It is well-positioned to benefit from secular growth until 2035, making it one of the best oversold small-cap names right now.

Back on March 20, Stifel analyst Jonathan Siegmann maintained a Buy rating for TAT Technologies Ltd. (NASDAQ:TATT), while increasing the price target from $47 to $60. His adjustment was based on an encouraging fourth-quarter performance. He described it as “another clean operating quarter.”

Siegmann noted that the company has been on a sustained trend of delivering strong top-line growth and margin expansion for 8 consecutive quarters.

TAT Technologies Ltd. (NASDAQ:TATT) offers services and solutions to the commercial and military aerospace and ground defense sectors. It designs heat transfer solutions such as pre-coolers and oil/fuel hydraulic heat exchangers, power electronics cooling systems, mechanical aircraft accessories, and more. It is also a provider of OEM and MRO services.

4. Burford Capital Ltd. (NYSE:BUR)

Burford Capital Ltd. (NYSE:BUR) is one of the 10 oversold small cap stocks to buy now.

On March 30, Wedbush downgraded Burford Capital Ltd. (NYSE:BUR) stock rating to Neutral from Outperform. The firm also cut down the target price from $6 to $4.75. This came after the company released a press statement regarding their stance on the decision by the U.S. Appeals Court concerning YPF.

In the statement, the company indicated that any fair value marks would trigger net worth requirements, which would prevent further debt issuance. Although there is no problem now, the limitation may lead to changes in the company’s growth plans to generate more cash. It introduces another dimension of risk in terms of financial considerations, along with legal risks that have been discussed earlier.

On March 30, Mark DeVries from Deutsche Bank decreased the price target for Burford Capital Limited (NYSE:BUR) from $17 to $15, while reiterating a Buy rating on the stock. Despite the downward revision in price target, the stock still yields more than 207% upside potential, which should garner investor interest in this oversold small-cap name.

DeVries reflected on the reversal issued by the U.S. Court of Appeals for the Second Circuit against a previous ruling issued by the District Court, which held the Argentine Republic accountable for a contract breach.

According to DeVries, the market’s performance since the first appeal hearing already suggested that this result was very likely. However, based on the facts of the case, the analyst still sees the final judicial reversal as highly unexpected and disappointing. Despite these immediate legal obstacles, DeVries asserts that the company remains significantly oversold at current trading levels.

Burford Capital Ltd. (NYSE:BUR) is a provider of legal finance goods and services globally. Its services include providing capital against the high-value litigation and arbitration cases, legal risk management, managing legal finance assets on behalf of third-party investors, and providing other services to the legal industry.

3. Viridian Therapeutics Inc. (NASDAQ:VRDN)

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 oversold small cap stocks to buy now.

On April 21, Truist reduced the price target on Viridian Therapeutics Inc. (NASDAQ:VRDN) from $36 to $33 while maintaining a Buy rating on the stock. Despite the downward revision in target price, the stock still offers an attractive upside potential of more than 140%, making it one of the best oversold small-cap names.

The firm is modifying its model based on revised assumptions around volume and pricing, keeping in mind a possible launch of Veli for both acute and chronic thyroid eye disease. It continues to hold positive sentiment towards the stock due to the visible catalysts ahead.

On April 8, Laura Chico from Wedbush maintained an Outperform rating for Viridian Therapeutics Inc. (NASDAQ:VRDN) while reducing the target price from $37 to $31. The analyst noted that over the past several years, the company has effectively managed a number of competitive threats in the industry.

However, Chico cautions that, in light of a recent pipeline update from Amgen on its Tepezza on-body injector, careful market observation is necessary. Using this different administration method, Amgen Inc. (NASDAQ:AMGN) reported a strong 57% placebo-adjusted proptosis response. Laura believes that the impending release of positive REVEAL-2 clinical results will continue to be the major catalyst for elegrobart’s value. For the second quarter of 2026, this crucial pipeline milestone is still well on schedule.

Viridian Therapeutics Inc. (NASDAQ:VRDN) is involved in discovering and selling treatments for rare and serious illnesses. It produces three main therapeutics, which include Veligrotrug, Elegrobart, and anti-thyroid-stimulating hormone receptor (TSHR). Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-008 and VRDN-006.

2. MiMedx Group Inc. (NASDAQ:MDXG)

MiMedx Group Inc. (NASDAQ:MDXG) is one of the 10 oversold small cap stocks to buy now.

On April 17, Northland reduced the price target on MiMedx Group Inc. (NASDAQ:MDXG) from $10 to $6, which still results in an adjusted upside of more than 75%. The firm also maintained an Outperform rating on the stock.

Northland is taking a conservative stance regarding the near-term performance of the company’s Wound Care business. However, it also notes that the market is heavily discounting the near-term disruption. Northland continues to see robust prospects for MiMedx’s Surgical segment. This supports a bullish argument in favor of this oversold small-cap name.

On April 17, Craig-Hallum reduced the price target from $10 to $7 for MiMedx Group Inc. (NASDAQ:MDXG) while reiterating a Buy rating. This downward adjustment still yields more than 104% upside potential for investors.

The firm lowered its forward financial projections after the corporate restructuring was announced by the company. Following the January 1 Medicare reimbursement drop, the company has mentioned a much slower-than-expected recovery throughout its core Wound Care division. The firm has noted that MiMedx is rapidly implementing targeted operating expense reductions totaling $40 million annually. As a part of this aggressive cost-cutting exercise, the Chief Operating Officer post will be immediately eliminated, coupled with broader executive salary cuts.

MiMedx Group Inc. (NASDAQ:MDXG) develops and sells placental tissue allografts to several sectors of the healthcare industry. It is involved in the processing of human placental tissues, the membrane, the umbilical cord, and the placental disc. It offers a range of wound care products, including Regentkit wound gel, Epicord, Epixpress, Choriofix, and more.

1. Maze Therapeutics Inc. (NASDAQ:MAZE)

Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the 10 oversold small cap stocks to buy now.

As of the April 24 closing, the consensus sentiment around the stock was strongly bullish. It received Buy ratings from all 12 analysts who provided coverage. Moreover, it offers almost 150% upside potential, based on a median 1-year price target of $64.45, making it one of the most attractive small-cap picks.

The bullish views are also backed by the company’s latest trial outcomes. Back on March 25, Maze Therapeutics Inc. (NASDAQ:MAZE) revealed encouraging results from the Phase 2 HORIZON trial on MZE829, an oral drug inhibiting APOL1, in treating a range of APOL1-induced kidney diseases. 12 weeks of administration of the drug brought about a 35.6% reduction in the mean value of albumin/creatinine ratio in broad AMKD patients, where 50% of patients had a reduction exceeding 30%.

Patients diagnosed with FSGS condition recorded a reduction in mean value by 61.8%, while those suffering from non-diabetic AMKD saw a reduction by 48.6%. There were no severe side effects. Maze intends to move the drug into a pivotal program. Harold Bernstein, President of R&D and Chief Medical Officer, stated that the results demonstrate encouraging proof of concept for the precision medicine treating the cause of AMKD.

Maze Therapeutics Inc. (NASDAQ:MAZE) is a developer of small-molecule precision medicines for the treatment of kidney and metabolic illnesses. The company’s lead programs include MZE829, APOL1, and MZE782. Additionally, it is also involved in the development of MZE001. The company has agreements with various organizations for licensing and commercialization of its products.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.